AstraZeneca Starts Clinical Trial Testing Its COVID-19 Treatment Antibody Cocktail

All eyes are on AstraZeneca's (NYSE: AZN) coronavirus vaccine AZD1222, which is in late-stage testing and could be on the market in October.

But the U.K.-based pharma is still hedging its bets, launching a phase 1 clinical trial for AZD7442, a treatment for COVID-19.

AZD7442 is a mixture of two antibodies that were isolated from patients infected with SARS-CoV-2, the coronavirus that causes COVID-19. AZD7442 is manufactured in a plant, unlike convalescent plasma that received an emergency use authorization on Sunday, which is collected from plasma of recovered patients. The purity of AZD7442 will increase the consistency of the product, but there are no guarantees the two antibodies AstraZeneca picked will block the virus in patients.

AstraZeneca will initially test AZD7442 in 48 healthy volunteers before moving the product into larger phase 2 and phase 3 studies, assuming the treatment is safe and tolerable. In addition to being used as a treatment for infected patients, AZD7442 could also be used as a preventative measure in patients who had been exposed to people infected with the coronavirus. Doctor in personal protective equipment talking to a patient

Image source: Getty Images.

AZD7442 trails Regeneron Pharmaceuticals' (NASDAQ: REGN) two-antibody-cocktail REGN-COV2, which is being tested in two phase 2/3 clinical trials for the treatment of COVID-19 and in a single phase 3 study for the prevention of COVID-19 in household contacts of infected individuals. The biotech recently teamed up with Roche (OTC: RHHBY) to help increase production and distribution of REGN-COV2, assuming it gains regulatory approval.

AstraZeneca's phase 1 study is being funded by the U.S. Defense Advanced Research Projects Agency and the U.S. Biomedical Advanced Research and Development Authority, so even if AZD7442 isn't needed because one or more of the vaccines and/or REGN-COV2 are largely successful, the hedge won't cost the drugmaker much.

10 stocks we like better than AstraZeneca
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AstraZeneca wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of August 1, 2020


Brian Orelli, PhD and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More